Mongersen

Drug Profile

Mongersen

Alternative Names: GED-0301

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Giuliani
  • Developer Celgene Corporation
  • Class Anti-inflammatories; Antisense oligonucleotides
  • Mechanism of Action Smad7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Ulcerative colitis

Most Recent Events

  • 08 Aug 2017 Celgene completes a phase II trial in Ulcerative colitis (Treatment-experienced) in Poland, Slovakia, Hungary, Bulgaria, Canada and USA (PO) (NCT02601300)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Celgene Corporation completes a phase I pharmacokinetics trial in Ulcerative colitis (In volunteers) in United Kingdom (PO) (NCT02957474)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top